Urgent RITZ cracker sandwich recall; labeling error could cause life-threatening allergic reactions: FDA
Ohio Sam's Club has wrong gasoline in pump, causing vehicle issues for customers
According to the FDA, Mondelēz Global LLC is voluntarily recalling four carton sizes of RITZ cracker sandwiches. The cartons contain individually wrapped packs of RITZ sandwiches that may be incorrectly labeled as Cheese variety, even though the product may be a Peanut Butter variety.
The recall alert goes on to explain that all outer cartons of the cracker sandwiches are labeled correctly and provide an allergen advisory statement indicating that the product 'contains peanuts.' However, the individually wrapped packs are of concern.
'People who have an allergy or severe sensitivity to peanuts may risk serious or life-threatening allergic reactions by consuming this product,' reads the FDA alert.
Mattel introduces first Barbie with type 1 diabetes
According to the FDA, the recall was initiated after the company discovered that film packaging rolls used to package individually wrapped products containing peanut butter may contain defects due to a supplier error.
'Corrective actions are being taken to help ensure this issue does not recur,' states the recall alert.
The recalled cracker sandwiches were sold nationwide. Here's what to check for:
Product Description
Retail UPC
Best When Used By Dates
Product Images
11.4 oz. RITZ Peanut Butter Cracker Sandwiches– 8 Count (8 x 1.38-oz. 6-pack carton)
0 44000 88210 5
1 NOV 25 – 9 NOV 25'AE' Plant Code Only (located on top of package)
See Image Below
27.6 oz. RITZ Peanut Butter Cracker Sandwiches– 20 Count (20 x 1.38-oz. 6-pack carton)
0 44000 07584 2
1 NOV 25 – 9 NOV 252 JAN 26 – 22 JAN 26'AE' Plant Code Only (located on top of package)
See Image Below
55.2 oz. RITZ Peanut Butter Cracker Sandwiches– 40 Count (40 x 1.38-oz. 6-pack carton)
0 44000 07819 5
1 NOV 25 – 9 NOV 252 JAN 26 – 22 JAN 26'AM' Plant Code Only (located on top of package)
See Image Below
27.3 oz. RITZ Filled Cracker Sandwich20-Count Variety Pack(20 packs of 10 Cheese 1.38-oz. packsand 10 Peanut Butter 1.38-oz. packs)
0 44000 08095 2
2 NOV 25 – 9 NOV 25'RJ' Plant Code Only (located on top of package)
See Image Below
The individually wrapped package incorrectly labeled as Cheese variety inside the cartons identified in the grid above may look like this:
Product Description
Retail UPC
Best When Used By Dates
Product Images
RITZ Cheese Cracker Sandwiches (1.38oz. pack)
0 44000 00211 4
1 NOV 25 – 9 NOV 252 JAN 26 – 22 JAN 26'AE' Plant Code Only (located on side of package)
See Image Below
The FDA advises consumers who have a peanut allergy should not eat these products and should discard the cracker sandwiches.
CLICK HERE for complete details on the recalled cracker sandwiches.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
Bloomberg
16 minutes ago
- Bloomberg
Reinstated CDC Officials Have ‘No Clue' Why They Were Brought Back
US Centers for Disease Control and Prevention officials who were laid off and subsequently reinstated have 'no clue' why, said Paul Schramm, chief of the agency's climate and health program. 'I wish I knew,' he said Tuesday at the Bloomberg Green Festival in Seattle. 'We don't know. There doesn't seem to be a rhyme or reason to it.'
Hamilton Spectator
23 minutes ago
- Hamilton Spectator
US appeals court upholds West Virginia restriction on abortion pill sales
CHARLESTON, (AP) — A federal appeals court on Tuesday upheld a lower court's decision to restrict abortion pill sales in West Virginia. A three-judge panel of the 4th U.S. Circuit Court of Appeals in Richmond, Virginia, affirmed a ruling by a U.S. district judge in 2023 despite federal regulators' approval of the abortion pill as a safe and effective medication. Most Republican-controlled states have enacted or adopted abortion bans of some kind, including restricting abortion pills by default, since the U.S. Supreme Court in 2022 overturned Roe v. Wade , the 1973 ruling that provided nationwide access to abortion. All have been challenged in court. The Supreme Court ruled in the case of Dobbs v. Jackson Women's Health Organization. U.S. District Court Judge Robert C. Chambers had ruled that the near-total abortion ban signed by then-Republican Gov. Jim Justice in September 2022 took precedence over approvals from the U.S. Food and Drug Administration. 'For us to once again federalize the issue of abortion without a clear directive from Congress, right on the heels of Dobbs, would leave us one small step short of defiance,' 4th Circuit Judge J. Harvie Wilkinson III wrote for the court. 'One can of course agree or disagree with the Dobbs decision. But that is not the point,' Wilkinson said. 'At a time when the rule of law is under blunt assault, disregarding the Supreme Court is not an option.' West Virginia Gov. Patrick Morrisey, who took office in January, had defended challenges to the abortion law when he served as attorney general. 'Big win out of the 4th Circuit today,' Morrisey said in a statement. GenBioPro Inc., the country's only manufacturer of a generic version of the abortion pill mifepristone, had argued that the state cannot block access to a FDA-approved drug. Chambers had dismissed the majority of GenBioPro's challenges, finding there is 'no disputing that health, medicine, and medical licensure are traditional areas of state authority.' Appeals judge DeAndrea Gist Benjamin concurred and dissented in part Tuesday, calling it a 'troubling opinion.' 'Put plainly, this law erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress,' Benjamin wrote. Not at issue in the appeal was a challenge by GenBioPro concerning a separate West Virginia law that stopped providers from prescribing mifepristone by telehealth. Chambers had allowed that challenge to proceed. The U.S. Supreme Court last year unanimously preserved access to mifepristone , which is used in nearly two-thirds of all abortions in the U.S. in 2023.
